ZA942809B - Treatment - Google Patents

Treatment

Info

Publication number
ZA942809B
ZA942809B ZA942809A ZA942809A ZA942809B ZA 942809 B ZA942809 B ZA 942809B ZA 942809 A ZA942809 A ZA 942809A ZA 942809 A ZA942809 A ZA 942809A ZA 942809 B ZA942809 B ZA 942809B
Authority
ZA
South Africa
Prior art keywords
treatment
Prior art date
Application number
ZA942809A
Inventor
Thomas Paul Blackburn
Guy Anthony Kennett
Gordon Smith Baxter
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ZA942809B publication Critical patent/ZA942809B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA942809A 1993-04-28 1994-04-22 Treatment ZA942809B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939308802A GB9308802D0 (en) 1993-04-28 1993-04-28 Treatment

Publications (1)

Publication Number Publication Date
ZA942809B true ZA942809B (en) 1995-10-23

Family

ID=10734635

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA942809A ZA942809B (en) 1993-04-28 1994-04-22 Treatment

Country Status (4)

Country Link
AU (1) AU6569794A (en)
GB (1) GB9308802D0 (en)
WO (1) WO1994025012A2 (en)
ZA (1) ZA942809B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
GB9700899D0 (en) * 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2377847T3 (en) 1999-01-13 2012-04-02 Bayer Healthcare Llc Diphenyl ureas substituted with omega-carboxy aryl as kinase inhibitors p38
CN1318404C (en) 2002-02-11 2007-05-30 拜耳制药公司 Aryl ureas as kinase inhibitors
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930702334A (en) * 1990-09-13 1993-09-08 데이비드 로버트 Indourea as a 5 hydroxytryptamine receptor antagonist
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
WO1993018028A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists

Also Published As

Publication number Publication date
WO1994025012A3 (en) 1994-12-22
AU6569794A (en) 1994-11-21
WO1994025012A2 (en) 1994-11-10
GB9308802D0 (en) 1993-06-09

Similar Documents

Publication Publication Date Title
GB9411080D0 (en) Treatment
GB9215633D0 (en) Novel treatment
GB9226860D0 (en) Novel treatment
GB9203039D0 (en) Treatment
GB9211148D0 (en) Novel treatment
GB9225860D0 (en) Novel treatment
GB9226957D0 (en) Novel treatment
ZA942809B (en) Treatment
GB9226958D0 (en) Produktionsaktieselskab) novel treatment
GB2274395B (en) Massager
ZA933376B (en) Novel treatment
GB9203637D0 (en) Novel treatment
GB9317306D0 (en) Effluent treatment
ZA948336B (en) Treatment
GB9310836D0 (en) Treatment
GB9225859D0 (en) Novel treatment
GB9314491D0 (en) Novel treatment
GB9215903D0 (en) Treatment
GB9200359D0 (en) Treatment
GB9206395D0 (en) Treatment
GB9203249D0 (en) Treatment
GB9200360D0 (en) Treatment
GB9210596D0 (en) Treatment
GB9200361D0 (en) Treatment
GB9321592D0 (en) Novel compounds and treatment